Latest Insights | BiopharmaTrend

The $1.8 Billion Bet That More Data Will Enable Progress in Virtual Cells

In October, Biohub, the Chan Zuckerberg science organization, expanded its Virtual Biology Initiative to $1.8 billion. The money pays for open, standardized data to train virtual cells: AI models that …

Continue ›››

The Virtual Cell Tracker: Who’s Building Them, What Works, Where the Money Goes

Latest changes · October 30, 2026 Biohub’s data push hit $1.8B with DOE, NIH, Google DeepMind, Isomorphic and Meta joining; commercial funders get a one-year head start on the data. One …

Continue ›››

Anthropic Files for IPO: S-1 Shows 9 of the 10 Largest Pharma Companies in the Fortune 500 Are Paying Customers

Anthropic filed for its IPO with the SEC on Monday, and its S-1 shows that 9 of the 10 largest pharmaceutical companies in the Fortune 500 each spent at least …

Continue ›››

13 AI Drug Discovery Companies to Watch in 2026

AI drug discovery has moved from platform pitches to clinical tests. One recent sign: in October 2026, Iambic Therapeutics raised $150 million in a Nasdaq IPO, saying in its filing …

Continue ›››

Benchling’s Science Foundries put teams of AI agents in charge of whole R&D workflows

With Science Foundries, launched today, the R&D software company moves from helping scientists with individual tasks to managing entire scientific processes with teams of AI agents. The launch builds on …

Continue ›››

When Agents Run Computations: Schrödinger’s Robert Abel On Where The Human Still Decides

Generating drug candidate ideas has become inexpensive, and the supply of hypotheses now exceeds any organization’s capacity to evaluate them. Schrödinger’s answer, launched at the end of July, is Bunsen: …

Continue ›››

WhiteLab Genomics Raises $26M to Scale AI-designed Delivery Systems for Cell and Gene Therapies

Techbio company WhiteLab Genomics has raised a $26 million Series B to develop and license its own AI-designed gene delivery technologies, moving beyond the computational services business it started with. …

Continue ›››

Is “Rescuing Failed Drugs with AI” a Category Now?

Inside the growing bet that AI can find the patients pharma's failed trials missed... Update (October 2026): Five months after this piece was first published, Biossil raised another $153 million …

Continue ›››

The $2.7B Question: How Do We Know If Isomorphic's AI Works?

Isomorphic Labs has raised about $2.7 billion from outside investors since 2025. Its president, Max Jaderberg, says its drug design engine works, but the company has not publicly named a …

Continue ›››

Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in Line

Recently, Iambic Therapeutics has filed to go public on Nasdaq under the ticker IAM, adding another closely watched name to a biotech IPO market that has begun to reopen after …

Continue ›››

Three AI Drug Discovery Startups Raise $526 Million in Two Days

Three AI drug discovery companies raised a combined $526 million on September 23 and 24. One mines plants and microbes for new medicines. One trains its models on what it …

Continue ›››

Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?

In the latest news, Novo Nordisk has entered a collaboration with Anthropic aimed at speeding the discovery and development of new medicines. An initial project will test Anthropic's Claude Science …

Continue ›››